文献速递肝病消化道肿瘤与早癌

DARS1通过非经典SAGA-MYC信号重塑肝细胞癌蛋白质组并促进侵袭性

Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through noncanonical SAGA-MYC signaling modulation.
PubMed 文献 · Hepatology · 2026-03-06

该研究探讨了天冬氨酰-tRNA合成酶1(DARS1)在肝细胞癌(HCC)中的临床与功能意义。DARS1在HCC中表达增高,尤其在侵袭性肿瘤和患者血浆中,其过表达增强体外侵袭性和体内成瘤能力,而遗传或药理阻断DARS1可损害干细胞特性而不影响正常样细胞。蛋白质组学显示DARS1过表达细胞中高天冬氨酸蛋白富集,且DARS1在核内与SAGA复合物成员(包括SUPT7L)相互作用,影响MYC调控,提示DARS1是HCC的潜在液体活检标志物和治疗脆弱点。

要点

  • DARS1在HCC中高表达,尤其在侵袭性肿瘤和患者血浆中可检测。
  • DARS1过表达增强HCC侵袭性和体内成瘤,阻断DARS1损害干细胞特性。
  • DARS1通过重塑蛋白质组和核内SAGA-MYC信号发挥非经典致癌作用。

核心结论

  • DARS1在HCC中频繁过表达并可于血浆中检测,支持其作为液体活检生物标志物的潜力。
  • DARS1是HCC的新脆弱点,通过蛋白质组重塑和与SAGA复合物的非经典核内相互作用调节MYC活性来发挥作用。

研究设计与样本

  • 研究评估了肿瘤与配对非肿瘤组织、计算机模拟队列和血浆样本中DARS1的表达。
  • 在肝癌细胞系中进行遗传和药理调控DARS1后的功能实验。
  • 使用异种移植和原位肿瘤模型进行体内验证。
  • 通过定量蛋白质组学表征DARS1的蛋白质相互作用物,并用生化方法确认。

主要发现

  • DARS1丰度在HCC中增加,尤其在高度侵袭性肿瘤和HCC患者血浆中。
  • DARS1过表达增加体外侵袭性以及体内异种移植和原位肿瘤形成,而遗传和药理阻断DARS1损害体外干细胞特性而不影响正常样细胞。
  • 蛋白质组分析显示DARS1过表达细胞中高天冬氨酸蛋白显著富集,表明HCC蛋白质组重塑。
  • DARS1在核内与SAGA转录辅激活物复合物成员(包括SUPT7L)相互作用,影响MYC调控;DARS1耗竭降低MYC蛋白水平、增加其磷酸化并增强药物诱导的衰老。

临床怎么用

  • DARS1可能作为HCC的液体活检生物标志物,通过血浆检测辅助诊断或监测。
  • 靶向DARS1可能成为HCC治疗策略,尤其针对侵袭性肿瘤,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Aminoacyl-tRNA synthetases (ARSs) exert canonical and emerging noncanonical roles in cancer. Given the frequent alterations in aspartate metabolism in HCC, we investigated the clinical and functional significance of aspartyl-tRNA synthetase (DARS1) in HCC. APPROACH AND RESULTS: DARS1 expression was evaluated in tumor and matched nontumoral tissues, in silico cohorts, and plasma samples. Functional assays were performed in liver cancer cell lines after genetic and pharmacological modulation of DARS1. In vivo validation was conducted using xenograft and orthotopic tumor models. Protein interactors of DARS1 were characterized by quantitative proteomics and confirmed by biochemical approaches. DARS1 abundance was increased in HCC, especially in highly aggressive tumors, and in plasma from patients with HCC. DARS1 overexpression increased aggressiveness in vitro and xenograft and orthotopic tumor formation in vivo, while genetic and pharmacological blockade of DARS1 impaired stemness in vitro without affecting normal-like cells. Proteomic profiling revealed a significant enrichment of high-aspartate proteins in DARS1-overexpressing cells, demonstrating a reshaping of the HCC proteome. Beyond its canonical role, DARS1 was found in the nucleus interacting with members of the SAGA transcriptional coactivator complex, including SUPT7L. This interaction affected MYC regulation, as DARS1 depletion reduced MYC protein levels, increased its phosphorylation, and enhanced drug-induced senescence, linking DARS1-SAGA activity to MYC-driven oncogenic pathways. CONCLUSIONS: DARS1 is frequently overexpressed in HCC and detectable in plasma, supporting its potential as a liquid biopsy biomarker. Functionally, DARS1 represents a novel vulnerability of HCC, acting through both proteome reshaping and noncanonical nuclear interactions with the SAGA complex that modulate MYC activity.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hermán-Sánchez N, Fernández-Barrena MG, Alañón-Martínez PE, et al. Aspartyl-tRNA synthetase 1 (DARS1) reshapes hepatocellular carcinoma proteome and promotes aggressiveness through noncanonical SAGA-MYC signaling modulation. Hepatology. 2026. PMID: 41790991. doi:10.1097/HEP.0000000000001736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。